Back to results
US 2020/0138909 A1Published application
Glucokinase activator compositions for the treatment of diabetes
AssigneevTv Therapeutics LLC
InventorsMaria Carmen Valcarce Lopez, Tung Fong
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
Claims17
A method of reducing glycosylated hemoglobin HbA1c in a mammal by increasing the mammal's insulin sensitivity comprising:
- administering to the mammal a therapeutically effective amount of a liver-selective glucokinase activator in combination with a therapeutically effective amount of a GLP-1 analog or a pharmaceutically acceptable salt thereof,
- wherein the mammal has inadequate glycemic control.
A method of reducing glycosylated hemoglobin HbA1c in a human by increasing the human's insulin sensitivity comprising:
- administering to the human a therapeutically effective amount of a liver-selective glucokinase activator in combination with a therapeutically effective amount of a GLP-1 analog or a pharmaceutically acceptable salt thereof,
- wherein the human has impaired glucose metabolism,
- wherein the liver-selective glucokinase activator is {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.